Form 4: RxSight CFO Shelley Thunen Acquires 125,000 Stock Options

Shelley Thunen, CFO of RxSight, Inc., reports the acquisition of 125,000 stock options on February 27, 2025.

Summary

• On February 27, 2025, Shelley Thunen, the Co-President and Chief Financial Officer of RxSight, Inc. (RXST), acquired 125,000 stock options.
• The options have an exercise price of $28.21.
• The options vest monthly over a four-year period, commencing on February 27, 2025, subject to continued service.
• The options expire on February 26, 2035.
• Following the transaction, Ms. Thunen directly owns 125,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to the CFO suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a key executive like the CFO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the options is tied to continued service, suggesting an expectation of ongoing contributions from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like RxSight's.
• Comparable companies in the medical device space, such as Alcon or Johnson & Johnson Vision, also utilize stock options as part of their executive compensation plans to incentivize performance and retain key personnel.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of shareholders, incentivizing value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates